Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, researchers compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
CMS lists Wegovy as an eligible GLP-1 drug for the Bridge when used to reduce excess body weight and maintain weight reduction
Unlike other medications that may contribute to weight gain, GLP-1 medications help in losing weight by working with your bodys natural systems
Autoimmune disorders affect millions and can strike any organ
CharmanTJonesCRGPicklesASimonoffEBairdGHappF
